Display options
Cite
Dong Z, Yao H, Miao Z, et al. Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation. Biomed Rep. 2017;6(6):686-690doi: 10.3892/br.2017.896.
Dong, Z., Yao, H., Miao, Z., Wang, H., Xie, R., Wang, Y., Shang, Y., Gong, C., & Liang, Z. (2017). Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation. Biomedical reports, 6(6), 686-690. https://doi.org/10.3892/br.2017.896
Dong, Zengxiang, et al. "Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation." Biomedical reports vol. 6,6 (2017): 686-690. doi: https://doi.org/10.3892/br.2017.896
Dong Z, Yao H, Miao Z, Wang H, Xie R, Wang Y, Shang Y, Gong C, Liang Z. Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation. Biomed Rep. 2017 Jun;6(6):686-690. doi: 10.3892/br.2017.896. Epub 2017 Apr 20. PMID: 28584642; PMCID: PMC5449953.
Copy Download .nbib Format: NLM
Share it on

Biomed Rep. 2017 Jun;6(6):686-690. doi: 10.3892/br.2017.896. Epub 2017 Apr 20.

Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation.

Biomedical reports

Zengxiang Dong, Hong Yao, Zhuangzhuang Miao, Hao Wang, Rongsheng Xie, Ye Wang, Yingfang Shang, Chunlin Gong, Zhaoguang Liang

Affiliations

  1. Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

PMID: 28584642 PMCID: PMC5449953 DOI: 10.3892/br.2017.896

Abstract

The aim of the present study was to assess the efficacy and safety of the pharmacological conversion of persistent atrial fibrillation (AF) using amiodarone or/and ibutilide. Seventy-nine consecutive patients (48 males and 31 females; mean age, 64.6±11.2 years; range, 40-80 years) with non-valvular chronic AF lasting >7 days (range, 7-97 days) that were admitted to hospital for elective pharmacological cardioversion were randomly assigned to receive treatment with intravenous ibutilide (1 mg plus an additional 1 mg if required; n=39) or intravenous amiodarone (300 mg) plus intravenous ibutilide (1 mg; n=40). Success rates of cardioversion were 51.3% (20/39 patients) for ibutilide alone and 71.8% (28/39 patients) for amiodarone + ibutilide (P<0.05). A comparable increase in the QTc interval was observed in the two groups. It was observed that the co-administration of amiodarone and ibutilide was safer than ibutilide alone with regard to the risk of ventricular arrhythmia. Forty-eight patients of successful cardioversion were personally contacted for follow-up. The result indicated that the sinus rhythm maintenance time of the amiodarone + ibutilide group (4.36±2.44 months) was significantly higher than that of the ibutilide group (2.34±1.75 months; P<0.01). In conclusion, pretreatment with intravenous amiodarone + ibutilide for pharmacological cardioversion of persistent AF is considered to be more effective and safer than treatment with ibutilide alone.

Keywords: amiodarone; atrial fibrillation; cardioversion rate; ibutilide

References

  1. Heart. 1997 May;77(5):393-4 - PubMed
  2. Pharmacol Ther. 2011 Aug;131(2):221-41 - PubMed
  3. Am J Cardiol. 1997 Aug 15;80(4):458-63 - PubMed
  4. Circulation. 1989 Jul;80(1):34-42 - PubMed
  5. Heart. 2006 May;92(5):631-4 - PubMed
  6. Heart. 1998 Jun;79(6):568-75 - PubMed
  7. Int Heart J. 2014;55(3):244-8 - PubMed
  8. Europace. 2011 Mar;13(3):329-45 - PubMed
  9. Int J Cardiol. 2007 Jun 12;118(3):321-5 - PubMed
  10. Circulation. 1995 Mar 15;91(6):1799-806 - PubMed
  11. Int J Cardiol. 2003 Apr;88(2-3):157-66 - PubMed
  12. Int J Biomed Sci. 2014 Sep;10(3):217-20 - PubMed
  13. Eur Heart J. 2010 Oct;31(19):2369-429 - PubMed
  14. Circulation. 1997 Dec 16;96(12):4298-306 - PubMed
  15. Europace. 2009 Jan;11(1):70-4 - PubMed
  16. Int J Cardiol. 2012 Mar 22;155(3):362-71 - PubMed
  17. Med Pregl. 2014 Sep-Oct;67(9-10):334-7 - PubMed
  18. Arch Intern Med. 2006 Apr 10;166(7):719-28 - PubMed
  19. Circulation. 1996 Oct 1;94(7):1613-21 - PubMed
  20. Drugs. 1992 Jan;43(1):69-110 - PubMed

Publication Types